Avisa Pharma is a venture-backed healthcare company focused on revolutionizing the diagnosis of pulmonary infections. They have developed a rapid, point-of-care breath test that enables quick and accurate detection of virulent bacterial pathogens. Using their proprietary delivery systems, patients inhale or ingest unique drug substrates, which are then analyzed to determine the presence and level of bacterial load.

Avisa Pharma has successfully conducted clinical trials in cystic fibrosis, tuberculosis, and community-acquired pneumonia, validating the safety and efficacy of their technology. Currently, they are planning pivotal trials for ventilator-associated pneumonia, with an intention to submit an Investigational Device Exemption application to the U. S.

FDA in 2023. Looking ahead, Avisa Pharma aims to expand the application of their breath test to address a wider range of bacterial infections, including COPD, cystic fibrosis (CF), non-CF bronchiectasis, community-acquired pneumonia, and tuberculosis (TB). For more information, visit their website and subscribe to receive their press releases.

Avisa Pharma is driving innovation in pulmonary infection diagnosis for improved patient outcomes